Free Trial

AstraZeneca Plc $AZN Shares Newly Acquired by William Blair Investment Management LLC

AstraZeneca logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • William Blair Investment Management opened a new AstraZeneca position in the third quarter, acquiring 557,483 shares valued at approximately $90.8 million. Institutional investors and hedge funds collectively own 20.35% of the stock.
  • AstraZeneca reported quarterly EPS of $2.79, beating the $2.60 consensus, while revenue reached $16.21 billion and rose 6.5% year over year.
  • Analysts give the stock a consensus “Moderate Buy” rating, with an average price target of $206.67.
  • Five stocks to consider instead of AstraZeneca.

William Blair Investment Management LLC acquired a new position in shares of AstraZeneca Plc (NYSE:AZN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 557,483 shares of the company's stock, valued at approximately $90,809,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP lifted its stake in AstraZeneca by 313.0% in the 3rd quarter. Allworth Financial LP now owns 33,413 shares of the company's stock valued at $5,395,000 after acquiring an additional 25,322 shares in the last quarter. GKV Capital Management Co. Inc. grew its stake in shares of AstraZeneca by 14.8% during the 3rd quarter. GKV Capital Management Co. Inc. now owns 12,905 shares of the company's stock worth $2,100,000 after acquiring an additional 1,660 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company's stock worth $1,857,187,000 after acquiring an additional 355,456 shares in the last quarter. Legacy Trust bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $254,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of AstraZeneca by 0.9% in the third quarter. Russell Investments Group Ltd. now owns 2,052,004 shares of the company's stock valued at $334,070,000 after purchasing an additional 18,417 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN stock opened at $184.66 on Monday. The stock has a market cap of $286.40 billion, a P/E ratio of 26.12, a P/E/G ratio of 1.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The company has a fifty day moving average price of $168.82 and a two-hundred day moving average price of $180.20. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71.

AstraZeneca (NYSE:AZN - Get Free Report) last announced its quarterly earnings data on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating analysts' consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company's quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.38 EPS. As a group, equities analysts predict that AstraZeneca Plc will post 10.22 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Deutsche Bank upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Tuesday, September 15th. Nordea Equity Research upgraded shares of AstraZeneca from a "sell" rating to a "buy" rating in a report on Tuesday, October 13th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They issued an "outperform" rating for the company. Citigroup reiterated a "buy" rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Finally, Weiss Ratings upgraded shares of AstraZeneca from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, October 26th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $206.67.

Read Our Latest Analysis on AstraZeneca

AstraZeneca Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN - Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AstraZeneca Right Now?

Before you consider AstraZeneca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.

While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines